MARISA ISBELL: Open Payments
NPI 1194385229 · ASHEVILLE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,472 in 108 payments from 12 companies in 2025. Trend: 2023 $2,203 · 2024 $1,136 · 2025 $2,472
Food & beverage: $2,472
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $850 |
| Alkermes, Inc. | 18 | $420 |
| Neurocrine BioSciences, Inc. | 12 | $220 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $182 |
| E.R. Squibb & Sons, L.L.C. | 3 | $154 |
| Teva Pharmaceuticals USA, Inc. | 7 | $139 |
| Vanda Pharmaceuticals Inc. | 10 | $135 |
| Axsome Therapeutics, Inc. | 3 | $89 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Lundbeck LLC | 4 | $78 |
Products named: VRAYLAR, ARISTADA, INGREZZA, CAPLYTA, REXULTI, COBENFY, FANAPT, AUSTEDO XR.
Industry payments across NC — which companies pay providers there.
